Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi; Vlad Ratziu; Rohit Loomba; Mary E. Rinella; Quentin M. Anstee; Zachary Goodman; Pierre Bédossa; Andreas Geier; Susanne Beckebaum; Philip N. Newsome; David Sheridan; Muhammad Y. Sheikh; James F. Trotter; W Knapple; Eric Lawitz; Manal F. Abdelmalek; Kris V. Kowdley; Aldo J. Montaño‐Loza; Jérôme Boursier; Philippe Mathurin; Elisabetta Bugianesi; G. Mazzella; Antonio Olveira; Helena Cortez‐Pinto; Isabel Graupera; David Orr; Lise Lotte Gluud; Jean‐François Dufour; David E. Shapiro; Jason Campagna; Luna Zaru; Leigh MacConell; Reshma Shringarpure; Stephen A. Harrison; Arun J. Sanyal; Manal F. Abdelmalek; Gary A. Abrams; Humberto Aguilar; Aijaz Ahmed; Elmar Aigner; Guruprasad P. Aithal; Aftab Ala; William Alazawi; Agustı́n Albillos; Michael Allison; Sfa Al-Shamma; Raúl J. Andrade; Pietro Andreoné; M. Angélico; Victor Ankoma‐Sey; Quentin M. Anstee; Rodolphe Anty; Víctor Araya; Juan Ignacio Arenas Ruiz; Perttu Arkkila; Marty Arora; Tarik Asselah; Jennifer Au; Oyekoya T. Ayonrinde; Robert J. Bailey; Maya Balakrishnan; Kiran Bambha; Meena B. Bansal; Sidney Barritt; John Bate; Jorge Beato; Susanne Beckebaum; Jaideep Behari; Pablo Bellot; Ziv Ben Ari; Michael Bennett; Marina Berenguer; Benedetta Terziroli Beretta‐Piccoli; Thomas Berg; Maurizio Bonacini; Lucía Bonet; Brian B. Borg; Marc Bourlière; Jérôme Boursier; William D. Bowman; David Bradley; Marija Branković; Marius Braun; Jean-Pierre Bronowicki; Savino Bruno; Elisabetta Bugianesi; Cindy X. Cai; Amy Calderon; José Luís Calleja; Elizabeth J. Carey; Michal Carmiel; J.A. Carrión; Matthew C. Cave; Cristina Chagas; Tawfik N. Chami; Alan K. Chang; Allan Coates; Jeremy Cobbold; Charlote Costentin; Kathleen E. Corey

doi:10.1016/s0140-6736(19)33041-7

Keywords

Obeticholic acidInterim analysisMedicinePlaceboSteatohepatitisInterimInternal medicineFatty liverClinical trialDiseaseAlternative medicinePolitical sciencePathology

Affiliated Institutions

Related Publications

Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

Gregory C. Vernon , Ancha Baranova , Zobair M. Younossi

Aliment Pharmacol Ther 2011; 34: 274–285 Summary Background Non‐alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, and its worldwide prevalence co...

2011 Alimentary Pharmacology & Therapeutics 3042 citations

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Chris Estes , Quentin M. Anstee , M. Arias +28 more

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is ex...

2018 Journal of Hepatology 1893 citations

Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus

Nathalie C. Leite , Gil F. Salles , Antonio Luis Eiras de Araújo +2 more

Abstract Background/Aims: Diabetic patients have an increased prevalence and severity of non‐alcoholic fatty liver disease (NAFLD). We aimed to investigate the prevalence and th...

2008 Liver International 528 citations

Non-alcoholic fatty liver disease

Elizabeth E. Powell , Vincent Wai‐Sun Wong , Mary E. Rinella

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease continuum ...

2021 The Lancet 2416 citations

Non‐alcoholic steatohepatitis: What is it, and why is it important in the Asia–Pacific region?

Geoffrey C. Farrell

Abstract Non‐alcoholic steatohepatitis (NASH), is a critical link in the chain of metabolic fatty liver disorders that spans steatosis to cryptogenic cirrhosis. It is the hepati...

2003 Journal of Gastroenterology and Hepat... 233 citations

Publication Info

Year: 2019
Type: article
Volume: 394
Issue: 10215
Pages: 2184-2196
Citations: 1142
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1142

OpenAlex

Cite This

APA Style

                            
                                
                                    Zobair M. Younossi, 
                                
                                    Vlad Ratziu, 
                                
                                    Rohit Loomba
                                
                                et al.
                            
                            (2019). 
                            Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. 
                            The Lancet
                            , 394
                            (10215)
                            , 2184-2196.
                            https://doi.org/10.1016/s0140-6736(19)33041-7
                        

Identifiers

DOI: 10.1016/s0140-6736(19)33041-7